Harnessing immunotherapy to combat COVID-19 : A modern snake oil or silver bullet?
Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved..
Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain outcomes in clinical trials involving the anti-malarial (hydroxychloroquine), anti-viral (remdesivir) or the combination of anti-malarial/antibiotic (hydroxychloroquine/azithromycin) regimens have predisposed the physicians to distrust these "highly-touted" drugs for COVID-19. In this milieu, immunotherapy might be a credible modality to target or modify specific/non-specific immune responses that interfere with the survival of intracellular pathogens. This scientific review throws light on the epidemiology of COVID-19, its pathogenesis and the current clinical scenario of immunotherapeutics including convalescent plasma (CP), type-1 interferons (IFN-I) and human monoclonal antibodies (mAbs) to combat COVID-19. The treatment outcomes underscore that immunotherapy might be a reliable tool to assuage COVID-19-associated immunopathology. However, specific patient pool studies are warranted to ascertain the precise (re)purposing of immunotherapeutics for COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Therapie - 76(2021), 4 vom: 05. Juli, Seite 335-345 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gunjegaonkar, Shivshankar Malkarjun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.therap.2020.10.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327845333 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327845333 | ||
| 003 | DE-627 | ||
| 005 | 20231225201702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.therap.2020.10.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327845333 | ||
| 035 | |a (NLM)34238584 | ||
| 035 | |a (PII)S0040-5957(20)30190-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gunjegaonkar, Shivshankar Malkarjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Harnessing immunotherapy to combat COVID-19 |b A modern snake oil or silver bullet? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain outcomes in clinical trials involving the anti-malarial (hydroxychloroquine), anti-viral (remdesivir) or the combination of anti-malarial/antibiotic (hydroxychloroquine/azithromycin) regimens have predisposed the physicians to distrust these "highly-touted" drugs for COVID-19. In this milieu, immunotherapy might be a credible modality to target or modify specific/non-specific immune responses that interfere with the survival of intracellular pathogens. This scientific review throws light on the epidemiology of COVID-19, its pathogenesis and the current clinical scenario of immunotherapeutics including convalescent plasma (CP), type-1 interferons (IFN-I) and human monoclonal antibodies (mAbs) to combat COVID-19. The treatment outcomes underscore that immunotherapy might be a reliable tool to assuage COVID-19-associated immunopathology. However, specific patient pool studies are warranted to ascertain the precise (re)purposing of immunotherapeutics for COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 serotherapy | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Interferon type I | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 700 | 1 | |a Shanmugarajan, Thukani Sathanantham |e verfasserin |4 aut | |
| 700 | 1 | |a Arunsundar, Mohanasundaram |e verfasserin |4 aut | |
| 700 | 1 | |a Arjun, Uppuluri Varuna Naga Venkata |e verfasserin |4 aut | |
| 700 | 1 | |a Devi, Kadirrel |e verfasserin |4 aut | |
| 700 | 1 | |a Wankhede, Sagar Baliram |e verfasserin |4 aut | |
| 700 | 1 | |a Ravichandiran, Velayutham |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapie |d 1947 |g 76(2021), 4 vom: 05. Juli, Seite 335-345 |w (DE-627)NLM000023655 |x 1958-5578 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2021 |g number:4 |g day:05 |g month:07 |g pages:335-345 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.therap.2020.10.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2021 |e 4 |b 05 |c 07 |h 335-345 | ||